Answers are grounded in this paper and cite their sources.
This clinical trial analysis quantifies eligibility trends for HIV and viral hepatitis in oncology trials, indicating a shift towards inclusive practices.
e23011 Background: Exclusion of people with HIV or viral hepatitis can limit generalizability of immune checkpoint inhibitor (ICI) trial evidence. Despite growing emphasis on risk-stratified inclusion, prevalence and temporal trends of HIV/HBV/HCV eligibility language remain incompletely characterized. We quantified these patterns in ICI oncology trials on ClinicalTrials.gov. Methods: Interventional ICI oncology trials first posted 2010–2025 on ClinicalTrials.gov were included (N = 8,924). Eligibility criteria were parsed with transparent, section-aware rule-based NLP at the criterion-line level and aggregated to trial-level classifications via prespecified precedence. For HIV/HBV/HCV, language was categorized as no mention, absolute exclusion, conditional eligibility, or mention–unclear. Primary HIV absolute exclusion was blanket exclusion for explicit HIV-positive status/known HIV infection/AIDS (strict); sensitivity included HIV-test–positive exclusions. HBV/HCV absolute exclusion was explicit chronic/known infection or serologic/virologic positivity without conditional qualifiers; conditional eligibility allowed controlled/suppressed/treated infection or limited exclusions to active/uncontrolled/detectable infection. Prevalence was summarized overall and by era (2010–2014, 2015–2019, 2020–2025). Temporal trends used adjusted logistic regression (binomial GLM, logit) estimating OR/year, adjusted for phase and industry sponsorship. Results: HIV/HBV/HCV language: no mention 2,345 (26.28%); conditional eligibility for ≥1 infection 5,352 (59.97%); absolute exclusion for ≥1 infection 990 (11.09%; sensitivity 12.19%, similar temporal pattern); mention–unclear 237 (2.66%). Infection-specific absolute exclusion was 9.72% (HIV), 1.48% (HBV), 0.30% (HCV). By era (2010–2014/2015–2019/2020–2025; n = 336/3,429/5,159), absolute exclusion for ≥1 infection was 10.12%/13.09%/9.83% and conditional eligibility 43.45%/64.30%/58.17%. Adjusted models showed decreasing HIV absolute exclusion (OR/year 0.956, 95% CI 0.935–0.977; p = 5.97×10⁻⁵) and absolute exclusion for ≥1 infection (OR/year 0.959, 95% CI 0.940–0.980; p = 9.25×10⁻⁵). HBV/HCV absolute exclusion was uncommon (132/27 events) with no significant temporal change. Stratified manual validation evaluated classification performance (n = 1,659). Conclusions: In ICI oncology trials posted 2010–2025, conditional eligibility for HIV/HBV/HCV was common, yet absolute exclusion persisted in ~1 in 9 trials (strict), peaking in 2015–2019 and declining in 2020–2025 largely due to decreasing HIV blanket exclusion. These findings support standardizing risk-stratified, evidence-based eligibility language to improve trial representativeness while maintaining safety.
No takes yet. Share an insight, caveat, or question.
Dharia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: